Extended Data Fig. 9: TRIM15 expression in treated and untreated melanoma specimens, and correlation of high TRIM15 and low CYLD expression with poor prognosis of melanoma patients.
From: TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination
a, TRIM15 expression in eleven melanoma samples that initially responded but subsequently progressed on the combined treatment of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib (treated), and nine matched pre-treatment tumor samples (untreated), based on the microarray dataset (GSE61992)56. The minimum, 25% percentile, median, 75% percentile, maxima are -9.271, -8.848, -8.118, -6.084, and -4.756, respectively, for untreated group; and -9.734, -7.84, -5.619, -4.041, and 3.549, respectively, for treated group. b, c, Average TRIM15 expression in 38 tumors that were treated the BRAF inhibitor dabrafenib or vemurafenib but subsequently progressed (treated) and 21 matched pretreatment tumors (untreated) (b), and TRIM15 expression in 21 matched treated and untreated samples (c). Note that TRIM15 was highly upregulated in two samples (#6 and #21). The results are from the microarray dataset (GSE50509)57. For b, the minimum, 25% percentile, median, 75% percentile, maxima for are -5.492, 1.99, 3.811, 9.627, and 13.59, respectively, for untreated group; and -4.804, 1.927, 4.814, 11.56, and 35.71, respectively, for treated group. d, Frequency of TRIM15 alterations in cancers (cBioPortal). e, CYLD mRNA expression in normal skin and SKCM. Results were analyzed on GEPIA website. **** P < 0.0001, two-sided Student’s t-test. f, Poor survival of melanoma patients with low CYLD expression. Results were analyzed on GEPIA website.
